Positive multi-center COPD trial with inhaled Bimosiamose
Revotar Biopharmaceuticals AG announced that it successfully completed a multi-center Phase II trial to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic obstructive pulmonary disease (COPD). Data have been accepted for the annual congress of the European Respiratory Society (ERS) in Amsterdam.
Inhalation of Bimosiamose for 28 days on top of standard bronchodilators was safe and well tolerated in 77 patients with moderate to severe COPD (GOLD II-III). It led to a broad and significant attenuation of airway inflammation and trend towards lung function improvements.
"Our data with Bimosiamose demonstrate a significant step forward in the anti-inflammatory treatment of COPD", said Prof. Wolfgang Meyer-Sabellek, CMO of Revotar. "We will discuss future clinical development of our first in class inhaled drug with international key opinion leaders in Amsterdam at one of the biggest and renowned respiratory conferences worldwide."
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Brachial_artery

Machine learning diagnoses pneumonia by listening to coughs - A new algorithm could spot early signs of respiratory diseases in hospitals and at home

Tricks of Ticking time bomb Hepatitis B Virus
Imperial and Tsinghua University launch seed fund for 'ambitious collaborations'
Membrane_transport
Abnova and Clearbridge BioMedics Accelerate Circulating Tumor Cell System into the Research and In Vitro Diagnostic Markets
